Leukotrienes are bronchoconstrictor and vasoactive lipid mediators that are targets in the
treatment of asthma. Although they are increasingly recognized to exert broad�…

As asthma and allergic respiratory diseases have reached epidemic proportions over the
last twenty years, research into the cellular and molecular pathogenesis of these disorders�…

Cysteinyl leukotrienes (CysLTs) are a family of inflammatory lipid mediators synthesized
from arachidonic acid by a variety of cells, including mast cells, eosinophils, basophils, and�…

The incidence of asthma has been positively associated with obesity. Asthma comprises
diverse “phenotypes” reflecting heterogeneity in a number of characteristics, including�…

The two cyclooxygenase isoforms, cyclooxygenase-1 and cyclooxygenase-2, both
metabolize arachidonic acid to prostaglandin H 2, which is subsequently processed by�…

Cyclic adenosine monophosphate (cAMP) was the original “second messenger” to be
discovered. Its formation is promoted by adenylyl cyclase activation after ligation of G protein�…

This review of leukotrienes, which are lipid mediators with a broad array of clinical effects,
and leukotriene receptors considers the biochemical and physiological aspects of these�…

The initial steps in the biosynthesis of leukotrienes from arachidonic acid are carried out by
the enzyme 5-lipoxygenase (5-LO). In intact cells, the helper protein 5-LO activating protein�…

Plasminogen activation to plasmin protects from lung fibrosis, but the mechanism underlying
this antifibrotic effect remains unclear. We found that mice lacking plasminogen activation�…

A new paradigm for asthma pathogenesis is presented in which exaggerated inflammation
and remodeling in the airways are a consequence of abnormal injury and repair responses�…